NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
Source: SeekingAlpha
2026-06-02 17:31:51 ET
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
NextCure, Inc. (NXTC) Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma Transcript
NextCure Inc.
NASDAQ: NXTC
NXTC Trading
-10.21% G/L:
$2.99 Last:
74,038 Volume:
$3.22 Open:
NXTC Latest News
June 04, 2026 08:00:00 am
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
June 01, 2026 08:00:00 am
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
May 07, 2026 04:05:00 pm
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
NXTC Stock Data
$63,376,182
4,271,908
0.43%
5
N/A
Biotechnology & Life Sciences
Healthcare
US
Beltsville
